Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration

Brain Research

Volumn 1497, Issue , 2013, Pages 1-14

  Kang, Ki Sung ^a   Yamabe, Noriko ^a   Wen, Yujing ^a   Fukui, Masayuki ^a   Zhu, Bao Ting ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

(+) Catechin; Catechol O methyltransferase (COMT); COMT inhibition; Levodopa; Neuroprotection; Oxidative neuronal damage

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHIN; CATECHOL METHYLTRANSFERASE; EPICATECHIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAINIC ACID; QUERCETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME INACTIVATION; HIPPOCAMPAL NEURODEGENERATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METHYLATION; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN METHYLATION; RAT; SIGNAL TRANSDUCTION; TEA;

ADRENERGIC UPTAKE INHIBITORS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHIN; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; FLUORESCEINS; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HYDROXYBENZOATES; KAINIC ACID; LEVODOPA; MALE; METHYLATION; MICE; NERVE DEGENERATION; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 84873082661     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.11.043     Document Type: Article

References (71)

1. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesia and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 2001 448 458
2. H. Bai, J.Y. Shim, and B.T. Zhu Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases Chem. Res. Toxicol. 20 2007 1409 1425
3. G. Bartholini, and A. Pletscher Decarboxylase inhibitors Pharmacol. Ther. 21 1975 407 421
4. F. Blandini, G. Nappi, R. Fancellu, A. Mangiagalli, A. Samuele, G. Riboldazzi, D. Calandrella, C. Pacchetti, G. Bono, and E. Martignoni Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease J. Neural Transm. 110 2003 911 922
5. R. Camicioli, M.M. Moore, A. Kinney, E. Corbridge, K. Glassberg, and J.A. Kaye Parkinson's disease is associated with hippocampal atrophy Mov. Disord. 18 2003 784 790
6. F. Catterall, L.J. King, M.N. Clifford, and C. Ioannides Bioavailability of dietary doses of 3H-labelled tea antioxidants (+)-catechin and (-)-epicatechin in rat Xenobiotica 33 2003 743 753
7. J.M. Cedarbaum, G. Leger, and M. Guttman Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in Cynomolgus monkeys: implications for the treatment of Parkinson's disease Clin. Neuropharmacol. 14 1991 330 342
8. L. Chen, M.J. Lee, H. Li, and C.S. Yang Absorption, distribution, elimination of tea polyphenols in rats Drug Metab. Dispos. 25 1997 1045 1050
9. D. Chen, C.Y. Wang, J.D. Lambert, N. Ai, W.J. Welsh, and C.S. Yang Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies Biochem. Pharmacol. 69 2005 1523 1531
10. H.J. Choi, K.S. Kang, M. Fukui, and B.T. Zhu Critical role of the JNK-p53-GADD45α apoptotic cascade in mediating oxidative cytotoxicity in hippocampal neurons Br. J. Pharmacol. 162 2011 175 192
11. F.C. Colpaert Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat Neuropharmacology 26 1987 1431 1440
12. C. Costa, C. Sgobio, S. Siliquini, A. Tozzi, M. Tantucci, V. Ghiglieri, M. Di Filippo, V. Pendolino, A. de Iure, M. Marti, M. Morari, M.G. Spillantini, E.C. Latagliata, T. Pascucci, S. Puglisi-Allegra, F. Gardoni, M. Di Luca, B. Picconi, and P. Calabresi Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease Brain 135 2012 1884 1899
13. M. Da Prada, H.H. Keller, L. Pieri, R. Kettler, and W.E. Haefely The pharmacology of Parkinson's disease: basic aspects and recent advances Experientia 40 1984 1165 1304
14. L. Dawson, A. Chadha, M. Megalou, and S. Duty The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat Br. J. Pharmacol. 129 2000 541 546
15. V.H. Denenberg, D.S. Kim, and R.D. Palmiter The role of dopamine in learning, memory, and performance of a water escape task Behav. Brain Res. 148 2004 73 78
16. J.L. Donovan, J.R. Bell, S. Kasim-Karakas, J.B. German, R.L. Walzem, R.J. Hansen, and A.L. Waterhouse Catechin is present as metabolites in human plasma after consumption of red wine J. Nutr. 129 1999 1662 1668
17. K.L. Eskow Jaunarajs, K.B. Dupre, C.Y. Ostock, T. Button, T. Deak, and C. Bishop Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat Behav. Pharmacol. 21 2010 627 637
18. S. Fahn Levodopa in the treatment of Parkinson's disease J. Neural Transm. 71 2006 1 15
19. M. Floreani, S.D. Skaper, L. Facci, M. Lipartiti, and P. Giusti Melatonin maintains glutathione homeostasis in kainic acid - exposed rat brain tissues FASEB J. 11 1997 1309 1315
20. M.G. Ferruzzi, J.K. Lobo, E.M. Janle, B. Cooper, J.E. Simon, Q.L. Wu, C. Welch, L. Ho, C. Weaver, and G.M. Pasinetti Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease J. Alzheimers Dis. 18 2009 113 124
21. C. Feuerstein, F. Serre, M. Gavend, J. Pellat, J. Perret, and M. Tanche Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation Acta Neurol. Scand. 56 1977 508 524
22. M. Fukui, J.H. Song, J.Y. Choi, H.J. Choi, and B.T. Zhu Mechanism of glutamate-induced neurotoxicity in HT22 mouse hippocampal cells Eur. J. Pharmacol. 617 2009 1 11
23. M. Fukui, H.J. Choi, and B.T.; Zhu Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death Free Radic. Biol. Med 4 2010 800 813
24. B. Georgievska, T. Carlsson, B. Lacar, C. Winkler, and D. Kirik Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor Eur. J. Neurosci. 20 2004 3121 3130
25. G. Gloire, S. Legrand-Poels, and J. Piette NF-kappaB activation by reactive oxygen species: fifteen years later Biochem. Pharmacol. 72 2006 1493 1505
26. C.G. Goetz Influence of COMT inhibition on levodopa pharmacology and therapy Neurology 50 1998 S26 S30
27. X. He, A.M. Jenner, W.Y. Ong, A.A. Farooqui, and S.C. Patel Lovastatin modulates increased cholesterol and oxysterol levels and has a neuroprotective effect on rat hippocampal neurons after kainate injury J. Neuropathol. Exp. Neurol. 65 2006 652 663
28. H. Heikkinen, J.G. Nutt, P.A. LeWitt, W.C. Koller, and A. Gordin The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease Clin. Neuropharmacol. 24 2001 150 157
29. H. Heikkinen, A. Varhe, T. Laine, J. Puttonen, M. Kela, S. Kaakkola, and K. Reinikainen Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose Br. J. Clin. Pharmacol. 54 2002 363 371
30. G. Hu, S. Bidel, P. Jousilahti, R. Antikainen, and J. Tuomilehto Coffee and tea consumption and the risk of Parkinson's disease Mov. Disord. 22 2007 2242 2248
31. P. Huot, M. Lévesque, and A. Parent The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea Brain 130 2007 222 232
32. S. Kaakkola, and R.J. Wurtman Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum J. Neurochem. 60 1993 137 144
33. B. Kandinov, N. Giladi, and A.D. Korczyn Smoking and tea consumption delay onset of Parkinson's disease Parkinsonism Relat. Disord. 15 2009 41 46
34. K.S. Kang, Y. Wen, N. Yamabe, M. Fukui, S.C. Bishop, and B.T. Zhu Dual beneficial effects of (-)-epigallocatechin gallate on levodopa methylation and hippocampal neurodegeneration: In vitro and in vivo studies PLoS One 5 2010 e11951
35. M. Karimi, J.L. Carl, S. Loftin, and J.S. Perlmutter Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levedopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid J. Chromatogr. B 836 2006 120 123
36. T. Keränen, A. Gordin, V.P. Harjola, M. Karlsson, K. Korpela, P.J. Pentikäinen, H. Rita, L. Seppälä, and T. Wikberg The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers Clin. Neuropharmacol. 16 1993 145 156
37. W.C. Koller, J.T. Hutton, E. Tolosa, and R. Capilldeo Immediate-release and controlled-release carbidopa/levodopa in PD: a 5 year randomized multicenter study Neurology 53 1999 1012 1019
38. K.R. Leaver, H.N. Allbutt, N.J. Creber, M. Kassiou, and J.M. Henderson Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection Brain Res. Bull. 80 2009 397 402
39. E.Y. Lee, H. Chen, J. King, and C. Charlton The role of 3-O-methyldopa in the side effects of L-DOPA Neurochem. Res. 33 2008 401 411
40. W.M. Loke, J.M. Hodgson, J.M. Proudfoot, A.J. McKinley, I.B. Puddey, and K.D. Croft Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men Am. J. Clin. Nutr. 88 2008 1018 1025
41. H. Lu, X. Meng, and C.S. Yang Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate Drug Metab. Dispos. 31 2003 572 579
42. C. Manach, O. Texier, C. Morand, V. Crespy, F. Régérat, C. Demigné, and C. Rémésy Comparison of the bioavailability of quercetin and catechin in rats Free Radic. Biol. Med. 27 1999 1259 1266
43. P.T. Mannisto, and S. Kaakkola Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors Pharmacol. Rev. 51 1999 593 628
44. Y. Matsuoka, Y. Kitamura, M. Okazaki, K. Terai, and T. Taniguchi Kainic acid-induced activation of nuclear factor-kB in rat hippocampus Exp. Brain Res. 124 1999 215 222
45. H.B. Matthews, G.W. Lucier, and K.D. Fisher Medicinal herbs in the United States: research needs Environ. Health Perspect. 107 1999 773 778
46. Y.J. Moon, L. Wang, R. DiCenzo, and M.E. Morris Quercetin pharmacokinetics in humans Biopharm. Drug Dispos. 29 2008 205 217
47. T. Müller Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference Patient Prefer. Adherence 3 2009 51 59
48. M. Nagai, A.H. Conney, and B.T. Zhu Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase Drug Metab. Dispos. 32 2004 497 504
49. J.V. Nalder, B.W. Perry, C. Gentry, and C.W. Cotman Degeneration of hippocampal CA3 pyramidal cells induced by intraventricular kainic acid J. Comp. Neurol. 192 1980 333 359
50. A. Padovani, C. Costanzi, N. Gilberti, and B. Borroni Parkinson's disease and dementia Neurol. Sci. 27 2006 S40 S43
51. A. Post, F. Holsboer, and C. Behl Induction of NF-κB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-κB and neuroprotection by antioxidants J. Neurosci. 18 1998 8236 8246
52. A. Raches, and S. Fahn O-Methyldopa interferes with striatal utilization of levodopa Ann. Neurol. 10 1981 94 95
53. P. Riederer, and S. Wuketich Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis J. Neural Transm. 38 1976 277 301
54. E. Rivas, M.L. de Ceballos, O. Nieto, and J.A. Fontenla In vivo effects of new inhibitors of catechol-O-methyl transferase Br. J. Pharmacol. 126 1999 1667 1673
55. A. Scalbert, and G. Williamson Dietary intake and bioavailability of polyphenols J. Nutr. 130 2000 2073S 2085S
56. B. Schmidt, D.M. Ribnicky, A. Poulev, S. Logendra, W.T. Cefalu, and I. Raskin A natural history of botanical therapeutics Metabolism 57 2008 S3 S9
57. L.C. Schmued, and K.J. Hopkins Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration Brain Res. 874 2000 123 130
58. G. Sêdek, K. Jorga, M. Schmitt, R.S. Burns, and P. Leese Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers Clin. Neuropharmacol. 20 1997 531 541
59. G. Segovia, F. Mora, A.R. Crossman, and J.M. Brotchie Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease Mov. Disord. 18 2003 138 149
60. N.S. Sharpless, M.D. Muenter, G.M. Tyce, and C.A. Owen Jr. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease Clin. Chim. Acta 37 1972 359 369
61. E.J. Shin, J.H. Jeong, A.Y. Kim, Y.H. Koh, S.Y. Nah, W.K. Kim, K.H. Ko, H.J. Kim, M.B. Wie, Y.S. Kwon, Y. Yoneda, and H.C. Kim Protection against kainate neurotoxicity by ginsenosides: attenuation of convulsive behavior, mitochondrial dysfunction, and oxidative stress J. Neurosci. Res. 15 2009 710 722
62. S. Tan, M. Wood, and P. Maher Oxidative stress induces a form of programmed cell death with characteristics of both necrosis and apoptosis in neuronal cells J. Neurochem. 71 1998 95 105
63. 11C]raclopride displacement and PET Neurology 46 1996 1430 1436
64. A. Toulouse, and A.M. Sullivan Progress in Parkinson's disease - Where do we stand? Prog. Neurobiol. 85 2008 376 392
65. H. Tohgi, T. Abe, T. Kikuchi, S. Takahashi, and Y. Nozaki The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease Neurosci. Lett. 132 1991 19 22
66. M.B. van Duursen, J.T. Sanderson, P.C. de Jong, M. Kraaij, and M. van den Berg Phytochemicals inhibit catechol-O-methyltransferase activity in cytosolic fractions from healthy human mammary tissues: implications for catechol estrogen-induced DNA damage Toxicol. Sci. 81 2004 316 324
67. M. Yamamoto Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background J. Neurol. 248 2001 III5 III11
68. B.T. Zhu, U.K. Patel, M.X. Cai, and A.H. Conney O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase Drug Metab. Dispos. 28 2000 1024 1030
69. B.T. Zhu Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis Curr. Drug Metab. 3 2002 321 349
70. B.T. Zhu CNS dopamine oxidation and catechol-O-methyltransferase (COMT): Importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease Int. J. Mol. Med. 13 2004 343 354
71. B.T. Zhu, J.Y. Shim, M. Nagai, and H.W. Bai Molecular mechanism for the high-potency inhibition of human catechol-O-methyltransferase by (-)-epigallocatechin-3-O-gallate Xenobiotica 38 2008 130 146